QNCX Stock Forecast & Price Target

Quince Therapeutics is well-positioned for success with its Phase 3 asset, eDSP, which has the potential to treat a rare pediatric neurodegenerative disease, A-T. The company's AIDE technology gives it a unique advantage, allowing for the encapsulation of drugs into a patient's own red blood cells, which could result in improved efficacy and safety compared to traditional treatments. With a strong financial backing and promising clinical trials, Quince Therapeutics has a positive outlook for future growth and success.

Quince Therapeutics is a late-stage biotechnology company with a single asset in LAM-001, a once-daily inhaled formulation of the mTOR-inhibitor rapamycin being developed for rare pulmonary diseases, with ongoing Phase 2 trials in pulmonary hypertension associated with interstitial lung disease (PH-ILD) and bronchiolitis obliterans syndrome (BOS) following lung transplantation and a third Phase 2 for sarcoidosis-associated PH starting soon. However, the company has a high clinical risk with ongoing Phase 2b study, only 10 patients in the dataset and systemic mTOR inhibition has been associated with adverse events. Additionally, the company has a long runway with its current balance sheet providing sufficient runway through 2028, but there is also a financial risk with ongoing net losses and potential need for additional capital. The market for PH-ILD is also becoming increasingly crowded, and Quince's success will depend on demonstrating a differentiated benefit. $6B in BOS and $9B in SAPH is projected for the company with these potential indications.